ProBio and Curocell Reach Major CAR‑T Commercialization Milestone

Unbeknownst to her, Jessica Martinsson’s long and varied career in research and life sciences was preparing her for her newest and possibly most influential role.

Lundbeck has reported headline results from the Phase IV THRIVE trial, in which 60% of migraine patients who had responded inadequately to a prior CGRP-targeting preventive therapy reported being "much" or "very much" improved after 24 weeks on Vyepti (eptinezumab).

It is once again time to honor extraordinary scientific discoveries. Will it be the GLP-1 pioneers – among them Denmark's Jens Juul Holst – optical coherence tomography, the wakefulness peptide orexin, or precision gene editing that is honored this year? Or will it be something completely different?

Karolinska Institutet's Center for Systems Infection Biology (CSIB) is being inaugurated today, October 2, at Campus Flemingsberg.

Stockholm-based Atrogi has reported positive human data for ATR-258, its first-in-class oral therapy designed to improve muscle function and body composition. Over eight weeks, treatment was associated with an approximately 13% improvement in lower-extremity muscle power, together with more lean mass and less fat mass.

Stockholm-based Mendus has presented updated five-year follow-up data from its completed ADVANCE II trial in acute myeloid leukemia (AML). It also gave an update on the ongoing VITAL-CML trial of its immunotherapy vididencel in chronic myeloid leukemia (CML). The data were presented at the Second Bologna Workshop on Immunotherapy for AML in Italy.

Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.